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Abstract
We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140)
candidate vaccine delivered vaginally to assess immunogenicity and safety. It was hypothesised that repeated delivery of
gp140 may facilitate antigen uptake and presentation at this mucosal surface. Twenty two healthy female volunteers aged
18–45 years were entered into the trial, the first receiving open-label active product. Subsequently, 16 women were
randomised to receive 9 doses of 100 mg of gp140 in 3 ml of a Carbopol 974P based gel, 5 were randomised to placebo
solution in the same gel, delivered vaginally via an applicator. Participants delivered the vaccine three times a week over
three weeks during one menstrual cycle, and were followed up for two further months. There were no serious adverse
events, and the vaccine was well tolerated. No sustained systemic or local IgG, IgA, or T cell responses to the gp140 were
detected following vaginal immunisations. Repeated vaginal immunisation with a HIV-1 envelope protein alone formulated
in Carbopol gel was safe, but did not induce local or systemic immune responses in healthy women.
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Introduction
The need to develop an effective HIV vaccine remains
imperative. There is growing evidence that an effective vaccine
against HIV-1 will need to induce broadly protective immune
responses at the virus portal of entry which can be recalled at
sufficient magnitude shortly after in vivo infectious challenge [1,2].
Our specific interest is to investigate vaccine strategies which
attempt to invoke persistent genital tract as well as systemic immune
responses that might be sufficient to block female receptive vaginal
HIV-1 transmission. Data from macaque SIV-challenge models
suggests that HIV is able to traverse the vaginal mucosa within a few
hours, and establish infection within 24 hours [3]. Although
systemic immunisation is able to block sexual transmission in
women of some pathogens (e.g. HPV) [4], it is not clear whether this
approach will be effective against HIV, which directly targets and
subverts the immune system. Therefore our goal is to investigate
novel vaccine strategies that might drive maximal anti-HIV-1
female genital tract mucosal immune responses.
Vaginal vaccination has been explored in women and female
non-human primates in a number of systems [5–10]. Although
some degree of response was reported in all of these experiments,
the antigens were usually co-administered with a local adjuvant,
such as recombinant cholera toxin B [7–10]. These studies
demonstrated that the efficiency of vaginal immunisation was
influenced by the menstrual cycle [9,10]. To circumvent this
variable we hypothesised that repeated exposure to antigen
throughout the menstrual cycle may be most likely to generate
an immune response. Furthermore, we used HIV-1CN54 clade C
recombinant trimeric envelope (gp140), which maintains CD4-
binding function, and is to some extent expected to emulate
natural exposure to HIV-1 envelope protein. We chose to avoid
the use of mucosal adjuvants in the vagina because of the inherent
dangers of up-regulating target cells and HIV transmission [11].
For the first human study in our programme, we therefore
determined whether nine vaginal immunisations with an HIV-1
envelope protein alone, administered throughout one menstrual
cycle, could induce genital tract and systemic immunity. We had
performed a series of toxicological, immunological, and formula-
tion studies in rabbits prior to the human trial, and were
encouraged by the results showing that formulations of the
CN54 gp140 trimer were well tolerated and induced both serum
and mucosal antibody responses after a single cycle of vaginal
immunisation [12,13].
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Methods
1.1 RCT
This was a randomised, placebo-controlled, double-blind phase
1 clinical trial. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. The trial was conducted at two
centres, the Vaccine Institute, St George’s, University of London,
and the Department of GU Medicine, York Hospital, York, UK.
We first gained regulatory, ethical, and governance approvals. All
volunteers gave fully informed written consent, and the trial was
conducted according to the UK Clinical Trials Regulations and
Good Clinical Practice guidelines.
1.2 Subjects, randomisation and interventions
Subjects were healthy female volunteers aged 18–45 years.
Potential participants were screened for medical abnormalities,
HIV, HBV, HCV, sexually transmitted infections and gynaecologic
disorders, and there was a range of other inclusion and exclusion
criteria. All women had to use condoms without a spermicidal
agent, and in addition use either combined oral contraception, a
diaphragm, or be sterilised. There was a total of 16 study visits over
4 menstrual cycles. The randomisation was computer generated by
an independent statistician using a 2:1 ratio of active: placebo and a
target population of 30. This was provided to Polymun Scientific
who prepared blinded individual subject doses. Corresponding IMP
supplies were used sequentially and provided to the sites in blocks of
five. The sample size was chosen based on expected side effects. The
first subject was given open label active product as a safety
precaution. The vaginal vaccines were prepared by bedside mixing
of the carrier gel plus the blinded study products [eitherCN54
gp140 (see below), or placebo buffer] and administered by the
volunteers at clinic visits nine times (3 times a week for 3 weeks)
during a single menstrual cycle following randomisation. Immuni-
sations were performed by insertion of 3 ml of active or placebo gel
into the vagina. Subjects were followed up for 8 weeks after the last
immunisation. We collected fractionated sera and peripheral blood
mononuclear cells (PBMC), plus endocervical and vaginal mucosal
secretions using Weck-CelTM surgical spears (MedtronicTM).
1.3 Primary and secondary outcomes
The primary outcomes were safety variables as comprised by
local cervico-vaginal AEs (epithelial disruption, erythema, or
Figure 1. Study flow chart (CONSORT diagram). All subjects screened, enrolled and randomised are detailed. All subjects randomised are
included in the safety and immunogenicity populations.
doi:10.1371/journal.pone.0025165.g001
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bleeding) and systemic AEs, either by report including diary card,
or by clinical examination including colposcopy, and laboratory
AEs. Adverse events, both local and systemic, and serious adverse
events were recorded and graded according to pre-defined criteria.
The secondary outcomes were immunological responses, (i) IgG &
IgA responses to CN54 gp140 in vaginal & cervical secretions and
serum, (ii) T-cell responses to HIV gp140 peptides in blood, and
(iii) T cell responses in cervical mononuclear cells.
1.4 Vaccines
We designed, expressed and produced under good manufac-
turing practice (GMP) a trimeric gp140 from a clade C envelope
clone p97CN54, kindly provided by H Wolf & R Wagner,
University of Regensburg, Germany. The trimeric gp140 (gp120
plus the external domain of gp41), designated as CN54 gp140, was
produced as a recombinant protein in CHO cells, and
manufactured to GMP specifications by Polymun Scientific,
Vienna, Austria (accession number AF286226). The fidelity of
the product was confirmed by mass spectrometry of tryptic
fragments by the Medical Biomics Centre at St George’s,
University of London. An aqueous gel using Carbopol 974P as
the matrix-former, and benzyl alcohol as preservative, was
designed for vaginal use by Particle Sciences, Bethlehem PA,
US. Directly before each immunisation the CN54 gp140 was
added to the gel vehicle, the mixture homogenised by multiple
passages between two interconnected syringes, and then loaded
into a vaginal applicator for administration. The final gel
formulation contained 33 mg/ml of gp140. A full battery of
toxicology, stability and rabbit vaginal irritation tests were
performed with this material with no significant adverse reactions
detected.
1.5 Genital tract secretions
Mucosal secretions were sampled using pre-weighed Weck-Cel
surgical spears placed either in the cervical os or against the
vaginal wall for 2 minutes. After reweighing, secretions were
eluted from the sponges using a modified version of a previously
described method [12]. In brief the spearheads (having absorbed
the vaginal secretions) were snipped into the top chamber of a
Spin-X tube (Corning) containing 300 ml of sterile filtered
extraction buffer [250 mM NaCl, 16 protease inhibitor cocktail
set 1 (Calbiochem) in phosphate buffered saline (PBS)]. The Spin-
X tubes were centrifuged at 4uC for 15 minutes at 13,000 g. A
repeat extraction was performed by adding an additional 300 ml
extraction buffer to the top chamber as described above. Then
8 ml of heat inactivated foetal calf serum was added to pooled
secretions from each sample site prior to separation into 200 ml
aliquots and freezing at 280uC before batch analysis by ELISA as
described below.
1.6 Cervical cytobrush sampling
Cervical cytobrush samples were collected at screening and
weeks 2, 3, 4, 6, and 8 weeks after the last immunisation. A
speculum was inserted into the vagina and the cytobrush
(CytobrushHplus, Medscan) was placed in the cervical os and
rotated twice through 360u. Cytobrushes were transferred to sterile
Table 1. Demographic characteristics of the randomised
subjects.
Placebo CN54gp140
Number of female subjects 5 16
Age at screening
Mean (SD) 27.0 (6.0) 26.3 (6.1)
Median 24.0 25.0
Range 23–37 20–43
Weight (kg)
Mean (SD) 58.7 (8.4) 62.5 (10.4)
Median 58.0 62.8
Range 48–69 50–85
Height (m)
Mean (SD) 1.65 (0.06) 1.63 (0.05)
Median 1.68 1.64
Range 1.57–1.70 1.55–1.72
Ethnicity (n)
White 5 13
Black 0 2
Asian 0 0
Other 0 1
doi:10.1371/journal.pone.0025165.t001
Table 2. Summary of adverse events in the randomised subjects.
Placebo CN54gp140
N=5 N=16
No. of events (mean) 29 (5.8) 125 (7.8)
No. of local and systemic reactions (mean) 18 (3.6) 72 (4.5)
No. of subjects with any event 5 16
No. of subjects with reproductive system adverse events 4 14
No. of subjects with gastrointestinal system adverse events 2 9
No. of subjects with nervous system adverse events 2 8
No. of subjects with general and administration site adverse events 3 4
No. of subjects with infection adverse events 0 7
Serious adverse events 0 0
Adverse event leading to withdrawal 0 1
doi:10.1371/journal.pone.0025165.t002
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15 ml tubes containing 3 ml transport medium, then placed on ice
prior to transport to the laboratory for processing and analysis.
1.7 Immunological assays
1.7.1 ELISA for antibody responses in serum and mucosal
secretions. Systemic IgG & IgA anti-gp140, and cervical and
vaginal total IgG & IgA, and anti-gp140 responses were
measured by ELISA. Antigen-specific ELISA assays were
initially standardised and optimised using a panel of serum
samples from 20 HIV negative and 20 HIV positive volunteers.
Briefly, 96 well microtitre plates were coated with 50 ml/well
CN54 gp140 at 5 mg/ml gp140 in PBS for 1 hour at 37uC. Plates
were then washed 4 times in PBST (PBS+0.05% Tween 20) and
blocked by adding PBST+10% FCS for 1 h at 37uC. After
washing 4 times as described dilutions of serum or mucosal
samples were added and incubated at 37uC for 1 hr. Bound
specific IgG or IgA responses were detected with either a goat
anti-human IgG-HRP (Sigma) or a goat anti-human IgA biotin
conjugate (a-chain specific, KPL laboratories) followed by
amplification with avidin peroxidise (Sigma). Following
developing by the addition of substrate and stop solution,
ELISA plates were read at 450 nm on a Versa Max microplate
reader (Molecular Devices). Only samples with absorbance
reading of $0.2 A450 (serum and mucosal) for antigen specific
IgG and $0.4 (serum) $0.2 A450 (mucosal) for specific IgA were
classified as a ‘response detected’, and these were then subjected
to endpoint titration, using the same ELISA antigen-specific
method described above.
1.7.2. ELISA for total IgG and IgA in mucosal secre-
tions. Total immunoglobulin concentrations in mucosal
secretions were measured by sandwich ELISA. Ninety-six well
microtitre plates were coated with either goat anti-human IgG
capture antibody (c-chain specific, Sigma) or goat anti-human IgA
(a-chain specific, Serotec) capture antibodies at 2 mg/ml. After
washing and blocking as described above mucosal secretions were
added and bound total IgG or total IgA detected with goat anti-
human IgG (Fc specific, Sigma) or IgA (a-specific, Serotec) HRP
conjugates and developed as described above. Standard curves
were derived using purified human IgG or IgA (Sigma, UK) and
concentrations in mucosal secretions calculated by taking into
account the dilution factor derived from the weight of the sample/
weight of sample +600(ml extraction buffer volume) assuming a
density of 1 mg/ml [8].
1.7.3. IFN-c ELISpot assay. Fractionated PBMC were
analysed for interferon-gamma (IFN-c) release following
stimulation with HIV clade C gp140 peptides and controls using
an ELISpot kitpro (Mabtech). Cryopreserved PBMC samples were
thawed, adjusted to 46106 cells/ml in R10 complete medium, and
rested overnight at 37uC in an atmosphere of 5% C02. Pre-coated
human IFN-c ELISpot plates (Mabtech) were washed and blocked
prior to the addition of stimulated PBMC. Viable PBMC were
stimulated with either 4 pools of 15mer peptides overlapping by 11
amino acids to cover the entire gp140 (pool 1: amino terminus of
gp120 to V1; pool 2: V2 to V3; pool 3: C3 to carboxy terminus of
gp120), pool 4: the entire external domain of gp41, a FEC control
peptide pool containing 32 peptides comprising human
cytomegalovirus, Epstein Barr virus and influenza virus MHC
class I restricted epitopes (ARP7099 CFAR, NIBSC) [14] or
polyclonal stimulation with PHA-P (as positive controls) all at a
concentration of 5 mg/ml or were unstimulated (negative controls)
with media alone. PBMC were plated in triplicate wells per
stimulus at 2.56105 cells per well. ELISpot plates were incubated
for 16–24 hours at 37uC 5% C02. After washing, bound IFN-c
producing cells were detected with anti-human IFN-c -ALP
labelled detection antibody and BCIP/NBT substrate according to
the manufacturer’s instructions. Spots were enumerated using an
automated ELISpot reader system and software (AID) and
expressed as spot forming units (SFU)/106 PBMC.
Figure 2. Serum anti-gp140 binding antibodies. Serum samples were screened by gp140-specific ELISA for IgG and IgA antibodies. Assay cut-
offs are shown (-------) based on the analysis of sera from 40 uninfected and unvaccinated women. Calibration results with sera from HIV-infected
women are shown in the upper panels. Trial participants failed to show positive binding when tested at each visit (lower panels). Representative
results are shown for 2 weeks post-last immunisation. * indicates non-specific binding of IgG obtained with sera from trial participant number 026,
detected throughout the course of the study period including pre-vaccination.
doi:10.1371/journal.pone.0025165.g002
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1.7.4. T cell enumeration in cervical cytobrush
samples. Cytobrush samples were processed within 4 hours of
collection. The brushes were squeezed with sterile forceps into the
transport medium to remove cells prior to centrifugation at 4uC
for 15 minutes at 4006g. Cell pellets were re-suspended in 3 ml
transport medium and counted by trypan blue exclusion for live
cells. If sufficient viable cells were obtained (.105 cells/ml) they
were stained for CD3 (APC), CD4 (PECy7) and CD8 (PE) markers
(Becton Dickinson). Parallel PBMC samples were used for
compensation settings on an FC500 flow cytometer (Beckman
Coulter) and the percentages of cells stained recorded.
Results
2.1 Study population
The trial was registered at ClinicalTrials.gov NCT00637962
and approved by the Wandsworth Research Ethics Committee no:
07/Q0803/29. The trial was carried out between October 2007
and October 2008. By October 2008 twenty two women had been
screened, were eligible, and had entered and completed the study
(Figure 1). No SAEs had been observed and at that point the Data
Monitoring Committee advised that the study had fulfilled its
objectives and could be terminated. Women were aged 20–43
years, with mean age 26 years, and 85% were of white ethnicity.
The first participant was treated with open-label active gp140
immunisations without significant event. Subsequent women were
randomised and received blinded product. When the randomisa-
tion code was broken it revealed that 16 women received active
product and 5 received placebo. The two randomisation groups
were well matched for demographic characteristics at entry
(Table 1).
2.2 Safety analyses
There were no serious adverse events reported. All adverse
events were enumerated and there were no significant differences
in the mean number of events per participant between groups
(Table 2). Many of these events were genitourinary symptoms,
including vaginal discharge, spotting, vaginal bleeding, vaginal
discomfort, etc. One subject received only 8 immunisations and
then withdrew consent due to irregular bleeding.
2.3 Immunogenicity analyses
2.3.1 Serum IgG and IgA gp140 binding
antibodies. Initially, a sensitive ELISA for the detection of
gp140-specific antibodies was developed. The saturating
concentration of recombinant gp140 for solid phase adsorption
was determined as 5 mg/ml by checkerboard titration of serum
and conjugate dilutions. Although this is a relatively high
concentration of antigen it was found to result in reproducible
and co-linear serum titration curves even with very low titre sera
which were negative in other assay formats (data not shown). For
gp140-specific serum IgA detection, the addition of an extra stage
of amplification using biotinylated anti-IgA and streptavidin-HRP
detector was found to give better discrimination between sera from
HIV infected subjects and uninfected individuals (data not shown).
The assays were calibrated using sera from 40 HIV-infected and
40 HIV-uninfected women and representative results are shown in
Figure 2. 100% specificity and sensitivity was obtained for the
detection of anti-gp140 IgG. For IgA antibody 100% specificity
and 87.5% sensitivity was obtained at a cut-off of A450 0.3;
however, 4 sera from uninfected subjects had values near the cut-
off so A450 0.4 was used for screening sera from the clinical trial
participants, reducing the sensitivity to 77.5%. Despite the use of
these sensitive, standardised assays, anti-gp140 binding antibodies
were detected in none of the trial participants (Figure 2).
Participant 026 had a relatively high background binding for
IgG antibody (at the cut-off) on both pre-vaccination visits but this
did not vary during the course of vaccination.
2.3.2 Cervico-vaginal immunoglobulins and anti-gp140
binding antibodies. First, total IgG and IgA content were
determined in cervical and vaginal samples taken longitudinally
from the trial participants. Total IgG and IgA in cervical and
vaginal secretions were detected reliably and reproducibly across
all visits (Figure 3a,b). Across the whole trial population, median
IgG concentrations were higher than IgA concentrations in both
cervical and vaginal samples (797 mg/ml versus 393 mg/ml and
267 mg/ml versus 68 mg/ml in cervix and vaginal respectively;
r,0.001; Wilcoxon signed rank test), and both IgG and IgA levels
were higher in cervical than vaginal secretions (r,0.001;
Wilcoxon signed rank test) (Figure 3c).
Next, using the anti-gp140 ELISA, we determined whether
eluates from Weck-Cel samples interfered with specific antibody
detection. Pools of cervical and vaginal secretions from HIV-
uninfected volunteers were spiked with HIV reference standard
serum and titrated in eluted mucosal fluid. Neither cervical nor
vaginal eluates had an effect on the linearity or gradient of the
titration curve. Titre of IgA binding antibody was essentially
unaltered and the titre of IgG was reduced by less than two-fold.
Having established that the gp140 ELISA assays performed
satisfactorily with mucosal secretions, the IgG and IgA binding
antibody ELISAs were validated in an operator blinded fashion
against a panel of 19 matched cervical and vaginal samples from
HIV-infected volunteers and a panel of 17 matched mucosal
samples from uninfected women. Antigen specific IgG antibody
detection was 100% sensitive and specific in both cervical and
vaginal samples (Fig. 4a). IgA binding antibody was also 100%
specific and had an overall sensitivity of 79% at an A450 0.1 cut-off
which was reduced to 63% at the A450 0.2 cut-off used in the
clinical trial. In three HIV-infected subjects IgA was detected only
in the cervical sample, in two subjects only in the vaginal sample
and in 10 subjects IgA antibody was detected in both mucosal
samples (Figure 4 b). Interestingly, vaginal samples were more
likely to contain higher levels of IgG antibody, as measured by
A450 at a dilution of 1/2, than the corresponding cervical samples
and this difference was statistically significant (r=0.014, Wilcoxon
signed rank test); however IgA antibody levels were not statistically
different (r=0.465).
IgG antibodies against gp140 were detected in neither cervical
nor vaginal samples from trial participants. 14/139 vaginal and 6/
139 cervical samples had IgA values above the cut-off (Figure 4 c).
However, in general end-point titres were low [2–14] with the
exception of the visit 15 vaginal samples from trial participant 001
with a titre of 100; however, no corresponding reactivity was seen
Figure 3. Total mucosal concentrations of IgG and IgA in trial participants. Immunoglobulin concentrations were corrected for sample
volume and plotted longitudinally for cervix (a) and vagina (b). Median concentrations of neither IgG or IgA showed significant changes over time in
either cervix or vagina. (c) Comparison of median concentrations showed that IgG concentrations were higher than IgA concentrations in both the
cervix and vagina and that concentrations of both immunoglobulin classes was higher in the cervix compared to the vagina. These differences were
statistically significantly at the r,0.001 level (***) (Mann Whitney ranked sum test). Box plots show 25th and 75th percentiles, error bars show 10th and
90th percentiles and median values are shown as (2).
doi:10.1371/journal.pone.0025165.g003
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in the paired cervical sample. Furthermore, 9/20 reactive IgA
samples were collected pre-immunisation and 7/20 were in
placebo vaccine recipients, so the reactivity did not reliably
indicate responses to the vaccine.
2.3.3. gp140-specific IFN-c T cell responses. In order to
calibrate the gp140-specific IFN-c ELISpot, a panel of 20
cryopreserved PBMC from HIV-infected and 20 samples from
uninfected volunteers were analysed in an operator-blinded
manner for reactivity against peptide pools from a clade C
gp140 sequence. Twelve of 20 samples from HIV-infected
individuals reacted specifically (Figure 5a). None of the samples
from uninfected individuals had specific reactivity, with
background frequencies well below the assay negative cut-off of
50 SFU/106 PBMC (Figure 5b). PBMC from 16 trial participants
had specific reactivity to the FEC pool with a median response of
2339 SFU/106 PBMC (Figure 5 c). Six of the 8 HIV-non
responders had responses to FEC and the frequency of reactive
cells was not significantly different to that in the HIV-responders
(r=0.85; Mann-Whitney sum rank test).
A total of 296 PBMC samples from trial participants were
analysed. Samples from 5 participants had non-antigen back-
ground signals above the cut-off on a maximum of two occasions
(range 55–132 SFU/106 PBMC) and on three occasions these
were in PBMC taken prior to vaccination. After background
subtraction only subject 001, who had received open label gp140
vaccine, had evidence of a weak peripheral T cell response of 50
and 71.7 SFU/106 PBMC against pools 2 and 4 respectively
present after 6 immunisations, which was then undetectable in the
subsequent menstrual cycle. All PBMC samples from trial
participants tested positive for responses to FEC and responses
in any one subject remained relatively stable throughout the
course of the study (Figure 5c). Comparison of pre-vaccination
results from the trial participants and from HIV uninfected
volunteer samples used for assay calibration revealed that the
median response was 788 SFU/106 PBMC i.e. significantly lower
than the median response in HIV-infected subjects (r=0.022;
Mann-Whitney rank sum test).
2.3.4. T cells from mucosal cytobrush. The feasibility of
analysing T cell phenotype and function in cells recovered from
cervical cytobrushing was evaluated. Paired PBMC and cervical
samples were collected from 30 HIV-infected women.
Lymphocyte populations were defined on PBMC samples and
used to select matched cervical cells. Using, this strategy, 16 of the
women had sufficient cervical T cells for further analysis. CD3+
cells were detected with a median frequency of 10% with a range
of 1.2 to 61% which was significantly less than the proportion of
CD3+ cells measured in PBMC (r,0.001; Wilcoxon signed rank
test) (Figure 6). Within this CD3+ population the CD8+ phenotype
predominated (median 38%); whereas CD4+ lymphocytes had a
median frequency of 27%. The proportion of CD4+ T cells was
significantly lower in cervical samples compared to that in
fractionated PBMC (r=0.009; Wilcoxon signed rank test).
However, analysis of samples taken from HIV-uninfected
individuals at a single time point revealed that the majority of
cytobrush samples had insufficient T cells for meaningful analysis.
Longitudinal samples were taken from the vaccine trial
participants; however, many of these proved unsuitable for
analysis. Nonetheless, results were obtained from 5 subjects on
one occasion and from 4 subjects on 2 occasions. CD3+ cells
were detected with a median frequency of 4.3% and a range of
1.4 to 14.1% this being a significantly smaller proportion than
in cytobrush samples from HIV-infected women (r,0.001;
Mann-Whitney rank sum test) (Figure 6). The proportion of
CD4+ T cells was usually higher than CD8+ cells in these
samples (data not shown). However, subject 002 had 87%
CD8+ T cells 2 weeks post-immunisations, and subject 025 had
69% CD8+ T cells 6 weeks post-immunisations but 31% 3
weeks post-immunisations and therefore this is unlikely to be
vaccine related.
Discussion
We conducted a novel randomised controlled trial of repeated
vaginal vaccination with an HIV envelope protein in healthy
young women. Recent vaginal vaccine trials have used cholera
vaccines including recombinant cholera toxin B (CTB), and given
promising results [7–10]. However, CTB is known to be a potent
mucosal adjuvant, and the doses administered were in the
milligram range. More recently, the immunogenicity of vaginally
administered recombinant hybrid soluble HIV-1 gp160 formulat-
ed with or without the cationic lipid mucosal adjuvant DC-
cholesterol was assessed in a phase 1 clinical trial [15]. A single
50 mg dose of vaccine was given in each of 3 menstrual cycles at
weeks 0, 4 and 8, although the timing of vaccine administration in
relation to the menstrual cycle was not specified. This study also
failed to detect serum or mucosal responses to the candidate
vaccine. The study reported here was markedly different in
providing a repeated exposure to gp140 antigen throughout the
menstrual cycle. We had conducted initial in vitro experiments and
shown that the gp140 antigen was efficiently eluted from the
carbopol carrier gel in an aqueous environment to 100% levels
over 20 minutes (data not shown). We were also encouraged by
pre-clinical safety data in rabbits demonstrating that repeated
vaginal delivery of gp140 without an adjuvant elicited systemic
IgG and mucosal cervico-vaginal IgG & IgA responses, including
anti-HIV-1 neutralising antibody responses [12,13]. The reasons
for the species differences in response to vaginal gp140 between
rabbits and humans may well relate to anatomical, histological and
physiological factors, as the rabbit female genital tract is quite
different to the human, with much of the cervico-vaginal tract
covered in columnar single-cell layer epithelium [16]. Further-
more, rabbits are induced ovulators and therefore will not
replicate the menstrual cycle effects on immune responsiveness
reported in women [9,10]. In order to facilitate future studies of
protective efficacy we also undertook, in parallel with this clinical
trial, a similar vaginal gp140 vaccination study in cynomolgus
macaques [17].
The strategy of para-clinical evaluation was adopted to allow
cross validation of immunogenicity between humans and ma-
caques using standardised assays. Interestingly, the results from the
macaque study showed that a similar immunisation regime
delivering nine intravaginal doses over one menstrual cycle also
failed to induce any detectable humoral or cellular responses, but
two additional monthly cycles of the same immunisation regime
Figure 4. Cervical and vaginal anti-gp140 binding antibodies. Cervical and vaginal samples were screened by gp140-specific ELISA for IgG
and IgA antibodies. Assay cut-offs are shown (-------) based on the analysis of secretions from 17 uninfected and unvaccinated women. Calibration
results from HIV+ volunteers for IgG (a) and IgA (b) are shown for cervix and vagina. Trial participants showed no IgG gp140 binding activity (data not
shown). (c) Sporadic anti-gp140 IgA binding activity (vertical histograms) was detected in cervical and vaginal samples from some vaccine trial
participants (participant No. shown in top left hand corner) and reactivity was not associated with total IgA (line plots) in either cervical or vaginal
samples. nd= not done.
doi:10.1371/journal.pone.0025165.g004
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Figure 5. Frequency of IFN-c secreting PBMC. (a) Calibration of the gp140-specific IFN- c ELISpot assay using PBMC from non-clade typed HIV1-
infected women. Vertical histograms show frequency of reactivity against each of four 15mer, overlapping by 11 peptide pools covering the total
length of gp140. Background non-specific reactivity is also shown. (-------) indicates the cut-off frequency for positivity based upon results from PBMC
taken from 20 uninfected non-vaccinated women (b). (c) With the exception of one trial participant on a single occasion (see text) no gp140-specific
reactivity was detected (not shown); however all participants had FEC-specific IFN- c secreting activity at every time point tested and the frequencies
of reactive cells remained relatively consistent.
doi:10.1371/journal.pone.0025165.g005
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lead to a significant systemic and mucosal antibody response in 2/
4 animals and primed a third animal for an anamnestic response.
Furthermore, the same intravaginal regimen was shown to boost a
single intramuscular immunisation of gp140 given with the AS01
adjuvant, and reciprocally that a single intramuscular immunisa-
tion was boosted by subsequent vaginal immunisation [17]. Taken
together, these data suggest that intravaginal immunisation with
non-adjuvanted gp140 inefficiently primes vaginal mucosal or
systemic immune responses, reflective of the lower genital tract
being a relatively inefficient immunological inductive site.
Nevertheless the boosting of parenteral immunisation seen in
macaques suggests that the same intravaginal formulation of
gp140 might be able to boost vaginal and systemic responses in
humans following priming by a different route of administration.
Although the Carbopol used in the vaginal formulation has been
shown to enhance immunogenicity when given parentally [18], we
have found no evidence that it has adjuvant properties when
applied mucosally in the concentration included in the gel.
Calibration and validation of immunological assays is critical for
reliable interpretation of clinical trial and pre-clinical data. This is
particularly challenging for mucosal samples that vary widely in
volume and composition. Here we used clinical materials from
HIV-infected and uninfected volunteers to standardise, optimise
and validate antigen-specific assays. Antibody assays applied to
sera gave robust performance. Despite the paucity of HIV-specific
IgA responses reported in serum and mucosal secretions of HIV-
infected individuals [19,20] our assay was sensitive enough to
detect anti-gp140 IgA antibodies in the majority of individuals
tested. Moreover, data from the macaque study demonstrated that
the recombinant gp140 used in the clinical trial is capable of
eliciting IgA responses in serum and mucosal secretions [17].
Despite 100% specificity of the assay in validation tests it is
interesting that weak anti-gp140 IgA reactivity was observed in
14/139 vaginal and 6/139 cervical samples. This reactivity was
shown to be non-specific as it was observed both in some pre-
immune sera and placebo participants. Furthermore this reactivity
was not related to total concentration of IgA in the mucosal
samples. Non-specific IgA reactivity against the HIV envelope has
been previously described, although its association with HIV-
exposed uninfected status remains controversial [21,22]. In this
study all trial participants were classified as low risk. Significantly,
multiple exposures to gp140 at a concentration probably many
times higher than that seen in infectious semen failed to boost any
pre-existing non-specific reactivity to gp140. Vaccination with
either the active or placebo formulation had no effect on the total
IgA or IgG concentrations detected in the cervix or vagina and
although variability was seen between individuals the median
concentrations of IgG and IgA detected in the cervix were
remarkably similar to those reported by others [23] and in
cynomolgous macaques [17]. However, we found lower concen-
trations of total vaginal immunoglobulins, and IgG and IgA in
women, and IgG in macaques than previously reported.
Analysis of IFN-c secreting cells in PBMC from HIV-infected
individuals demonstrated that the gp140-ELISpot assay did not
require an exact sequence match to detect reactivity. As our cohort
of HIV-infected women were not virus-clade defined, it is likely
that non-responders were infected with non-clade C virus. Only
one trial participant demonstrated weak and transient gp140 T cell
reactivity. This was also the only subject displaying a relatively
high titre anti-gp140 IgA in the cervix. However, attempts to
analyse cervical T cell reactivity proved to be unsuccessful.
Although recovery of cells in sufficient numbers for meaningful
analysis has been achieved in HIV-infected multiparous women
[24,25] low yields have limited their usefulness [26]. Our results
bear this out. Even fewer T cells could be detected in cytobrushes
from healthy trial volunteers and where phenotype analysis was
possible, as expected, CD4+ cells predominated over CD8+ cells.
Preliminary experiments were undertaken using polyclonal
expansion of cells from HIV uninfected women using CD3 and
CD28 co-stimulation and a novel method using CD3 and CD137
co-stimulation in the presence of survival and anti anti-apoptotic
cytokines designed to bias expansion of CD8+ cells. However this
strategy was successful in only 4 of 16 samples tested (MM-
unpublished observations). Even if the efficacy of polyclonal
expansion could be improved, the rate-limiting step will remain
the number of precursor cells available from cytobrush samples.
Figure 6. Proportion of CD3+ lymphocytes in cervical cytobrush samples from HIV-infected and uninfected women. For each
individual the lymphocyte population was defined on PBMC by forward-side scatter profile and used to gate CD3+ cells recovered from the cervical
cytobrush. Box plots show 25th and 75th percentiles, error bars show 10th and 90th percentiles and median values are shown as (2). Comparison of
percentage CD3+ lymphocytes in PBMC from HIV-infected and HIV uninfected volunteers showed a statistically significant higher result in uninfected
subjects (***) (r,0.001; Mann Whitney ranked sum test) whereas in cervical samples a higher proportion of CD3+ lymphocytes were measured in HIV
infected volunteers (***) (r,0.001; Mann Whitney ranked sum test).
doi:10.1371/journal.pone.0025165.g006
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To summarise, we found no evidence for adverse safety
outcomes in association with the gp140 vaginal immunisation.
However, we observed frequent local AEs within both active and
placebo arms. Of note, the female participants in this trial disliked
both the multiple invasive (i.e. vaginal, by using a speculum)
sampling procedures, and vaginal product deliveries within the
clinic. We are currently evaluating new vaginal self-sampling
methods, and self-administered vaginal product delivery at home,
which within research studies would clearly be more acceptable
[27].
In conclusion, we have shown that it is feasible to conduct a
HIV vaccine phase 1 trial focussing intensely on measurement of
cervico-vaginal immune responses. We found no evidence in
humans that immunisation with the vaginal gp140 vaccine
candidate induced local or systemic immune responses. Further
studies in both macaques and humans will determine whether
priming by intramuscular or intranasal routes followed by vaginal
boosting with gp140 leads to enhanced local and/or systemic
responses.
Supporting Information
Checklist S1 CONSORT checklist.
(DOC)
Protocol S1 Trial Protocol.
(DOC)
Acknowledgments
We thank all the volunteers and trial participants for their assistance. We
thank Olanike Animasaun for obtaining cervical samples for the T cell
assay development in this study. The studies were integrated with efforts to
standardise HIV vaccine development through the EUROPRISE Network
of Excellence.
Author Contributions
Conceived and designed the experiments: DL TC MC RS CL. Performed
the experiments: CF AM RW MW AC CC RG MM. Analyzed the data:
DL TC MC CL. Contributed reagents/materials/analysis tools: SJ. Wrote
the paper: DL AC TC MC RS CL.
References
1. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal
transmission. Nature 464: 217–223.
2. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, et al. (2009) Visualizing antigen-
specific and infected cells in situ predicts outcomes in early viral infection.
Science 323: 1726–1729.
3. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. (2005) Propagation and
dissemination of infection after vaginal transmission of simian immunodeficiency
virus. J Virol 79: 9217–9227.
4. The GlaxoSmithKline vaccine HPV-007 study group (2009) Sustained efficacy
and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-
adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to
6.4 years. Lancet 374: 1975–1985.
5. Ogra LP, Ogra SS (1973) Local antibody response to poliovaccine in the human
female genital tract. J Immunol 110: 1307–1311.
6. Klavinskis LS, Bergmeier LA, Gao L, Mitchell E, Ward RG, et al. (1996)
Mucosal or targeted lymph node immunization of macaques with a particulate
SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and
draining lymph nodes. J Immunol 157: 2521–2527.
7. Wassen L, Schon K, Holmgren J, Jertborn M, Lycke N (1996) Local intravaginal
vaccination of the female genital tract. Scand J Immunol 44: 408–414.
8. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP (1997) Comparison of the
oral, rectal, and vaginal immunization routes for induction of antibodies in rectal
and genital tract secretions of women. Infec Immun 65: 1387–1394.
9. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al.
(2002) Differential induction of mucosal and systemic antibody responses in
women after nasal, rectal, or vaginal immunization: influence of the menstrual
cycle. J Immunol 169: 566–574.
10. Johannson EL, Wassen L, Holmgren J, Jertborn M, Rudin A (2001) Nasal and
vaginal vaccination have differential effects on antibody responses in vaginal and
cervical secretions in humans. Infec Immun 69: 7481–7486.
11. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, et al. (2005) The Toll-
like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN,
induce antiviral cytokines and chemokines but do not prevent vaginal
transmission of simian immunodeficiency virus when applied intravaginally to
rhesus macaques. J Virol 79: 14355–14370.
12. Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, et al. (2010) Repeated
vaginal administration of trimeric HIV-1 clade C gp140 induces serum and
mucosal antibody responses. Mucosal Immunol 3: 57–68.
13. Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, et al. (2009)
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope
protein CN54gp140 within novel rheologically structured vehicles elicits specific
immune responses. Vaccine 27: 6791–6798.
14. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, et al. (2002) A panel
of MHC class I restricted viral peptides for use as a quality control for vaccine
trial ELISPOT assays. J Immunol Methods 260: 157–172.
15. Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, et al. (2008)
Phase 1 study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/
LAI) administered by the mucosal route to HIV-seronegative volunteers: the
ANRS VAC14 study. Vaccine 26: 2657–2666.
16. Barberini F, Correr S, De Santis F, Motta PM (1991) The epithelium of the
rabbit vagina: a microtopographical study by light, transmission and scanning
electron microscopy. Arch Histol Cytol 54: 365–378.
17. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. (2011)
Antibody responses after intravaginal immunisation with trimeric HIV-1CN54
clade C gp140 in Carbopol gel are augmented by systemic priming or boosting
with an adjuvanted formulation. Vaccine 29: 1421–1430.
18. Krashias G, Simon A-K, Wegmann F, Kok WL, Ho LP, et al. (2010) Potent
adaptive immune responses induced against HIV-1 gp140 and influenza virus
HA by a polyanionic carbomer. 28: 2482–2489.
19. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, et al. (1999)
Comparison of the distribution of IgG and IgA antibodies in serum and various
mucosal fluids of HIV type1-infected subjects. AIDS Res Hum Retroviruses 15:
1365–1376.
20. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC (2009) Mucosal
immunology of the genital and gastrointestinal tracts and HIV-1 infection.
J Reprod Immunol 83: 196–200.
21. Mestecky J, Wright P, Lopalco L, Staats HF, Kozlowski PA, et al. (2011) Scarcity
or absence of humoral immune responses in the plasma or cervicovaginal lavage
fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res
Hum Retroviruses 27: 469–486.
22. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, et al. (2009) HIV-1
gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-
seronegative individuals block HIV-1 epithelial transcytosis and neutralize
CD4(+) cell infection: an IgA gene and functional analysis. Mucosal
Immunology 2: 412–426.
23. Safaeian M, Kemp T, Falk RT, Rodriguez AC, Hildesheim A, et al. (2009)
Determinants and correlation of systemic and cervical concentrations of total
IgA and IgG. Cancer Epidemiol Biomarkers Prev 18: 2672–2676.
24. Kaul R, Thottingal P, Kimani J, Kiama P, Waigwa CW, et al. (2003)
Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in
the blood and genital tract of HIV-infected women. AIDS 17: 1139–1144.
25. Gumbi PP, Nkwanyana NN, Bere A, Burgers WA, Gray CM, et al. (2008)
Impact of mucosal inflammation on cervical human immunodeficiency virus
(HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic
HIV infection. J Virol 82: 8529–8536.
26. Bere A, Denny L, Burgers WA, Passmore J-A (2010) Polyclonal expansion of
cervical cytobrush-derived T cells to investigate HIV-specific responses in the
female genital tract. Immunology 133: 23–33.
27. Boskey ER, Moench TR, Hees PS, Cone RA (2003) A self-sampling method to
obtain large volumes of undiluted cervicovaginal secretions. Sex Transm Dis 30:
107–109.
HIV-1 GP140 Vaginal Vaccine
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25165
